Cell death in immune thrombocytopenia: Novel insights and perspectives

Seminars in Hematology

Volumn 50, Issue SUPPL.1, 2013, Pages

  Von Gunten, Stephan ^a   Wehrli, Marc ^a   Simon, Hans Uwe ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CASPASE 8; CASPASE 9; CYTOCHROME C; IMMUNOGLOBULIN; PHOSPHATIDYLSERINE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; THROMBOCYTE ANTIBODY; THROMBOPOIETIN;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL SURFACE; HUMAN; HUMORAL IMMUNITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MEGAKARYOCYTE; MEGAKARYOPOIESIS; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; THROMBOCYTE ACTIVATION; THROMBOCYTOPOIESIS; TOXIC EPIDERMAL NECROLYSIS;

ANIMALS; APOPTOSIS; AUTOANTIBODIES; BLOOD PLATELETS; CELL DEATH; HUMANS; MEGAKARYOCYTES; THROMBOCYTOPENIA;

EID: 84877662322     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.03.016     Document Type: Article

References (65)

1. Harrington W.J., Sprague C.C., Minnich V., Morre C.V., Aulvin R.C., Dubach R. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 1953, 38:433-469.
2. Shulman N.R., Marder V.J., Weinrach R.S. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci 1965, 124:499-542.
3. Cines D.B., Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med 2002, 346:995-1008.
4. Ballem P.J., Segal G.M., Stratton J.R., Gernsheimer T., Adamson J.W., Slichter S.J. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987, 80:33-40.
5. Leytin V. Apoptosis in the anucleate platelet. Blood Rev 2012, 26:51-63.
6. White M.J., Kile B.T. Apoptotic processes in megakaryocytes and platelets. Semin Hematol 2010, 47:227-234.
7. Houwerzijl E.J., Blom N.R., van der Want J.J.L., Vellenga E., de Wolf J.T.M. Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death. Leukemia 2006, 20:1937-1942.
8. Mason K.D., Carpinelli M.R., Fletcher J.I., et al. Programmed anuclear cell death delimits platelet life span. Cell 2007, 128:1173-1186.
9. Vanags D.M., Orrenius S., Aguilar-Santelises M. Alterations in Bcl-2/Bax protein levels in platelets form part of an ionomycin-induced process that resembles apoptosis. Br J Haematol 1997, 99:824-831.
10. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008, 9:47-59.
11. Josefsson E.C., James C., Henley K.J., et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med 2011, 208:2017-2031.
12. Debrincat M.A., Josefsson E.C., James C., et al. Mcl-1 and Bcl-xl coordinately regulate megakaryocyte survival. Blood 2012, 119:5850-5858.
13. Kodama T., Hikita H., Kawaguchi T., et al. Mcl-1 and Bcl-xl regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages. Cell Death Differ 2011, 19:1856-1869.
14. Geering B., Simon H.U. Peculiarities of cell death mechanisms in neutrophils. Cell Death Differ 2011, 18:1457-1469.
15. Jost P.J., Grabow S., Gray D., et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009, 460:1035-1039.
16. Radley J.M., Haller C.J. The demarcation membrane system of the megakaryocyte: a misnomer?. Blood 1982, 60:213-219.
17. Zauli G., Vitale M., Falcieri E., et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood 1997, 90:2234-2243.
18. Falcieri E., Bassini A., Pierpaoli S., et al. Ultrastructural characterization of maturation, platelet release, and senescence of human cultured megakaryocytes. Anat Rec 2000, 258:90-99.
19. De Botton S., Sabri S., Daugas E., et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 2002, 100:1310-1317.
20. Clarke M.C.H., Savill J., Jones D.B., Noble B.S., Brown S.B. Compartmentalized megakaryocyte death generates functional platelets committed to caspase-independent death. J Cell Biol 2003, 160:577-587.
21. Ogilvy S., Metcalf D., Print C.G., Bath M.L., Harris A.W., Adams J.M. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci U S A 1999, 96:14943-14948.
22. Bouillet P., Metcalf D., Huang D.C.S., et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999, 286:1735-1738.
23. Morison I.M., Cramer Borde E.M., Cheesman E.J., et al. A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia. Nat Genet 2008, 40:387-389.
24. Kozuma Y., Yuki S., Ninomiya H., Nagasawa T., Kojima H. Caspase activation is involved in early megakaryocyte differentiation but not in platelet production from megakaryocytes. Leukemia 2009, 23:1080-1086.
25. White M.J., Schoenwaelder S.M., Josefsson E.C., et al. Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function. Blood 2012, 119:4283-4290.
26. Houwerzijl E.J., Blom N.R., van der Want J.J.L., et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004, 103:500-506.
27. Pisciotta A.V., Stefanini M., Dameshek W. Studies on platelets. Blood 1953, 8:703-723.
28. Savill J., Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000, 407:784-788.
29. Erwig L.P., Henson P.M. Clearance of apoptotic cells by phagocytes. Cell Death Differ 2008, 15:243-250.
30. Heemskerk J., Bevers E., Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002, 88:186-193.
31. Bevers E.M., Comfurius P. Zwaal RFA. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta 1983, 736:57-66.
32. Jobe S.M., Wilson K.M., Leo L., et al. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood 2008, 111:1257-1265.
33. Schoenwaelder S.M., Yuan Y., Josefsson E.C., et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009, 114:663-666.
34. Catani L., Fagioli M.E., Tazzari P.L., et al. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol 2006, 34:879-887.
35. Winkler J., Kroiss S., Rand M.L., et al. Platelet apoptosis in paediatric immune thrombocytopenia is ameliorated by intravenous immunoglobulin. Br J Haematol 2011, 156:508-515.
36. Dowling M.R., Josefsson E.C., Henley K.J., Hodgkin P.D., Kile B.T. Platelet senescence is regulated by an internal timer, not damage inflicted by hits. Blood 2010, 116:1776-1778.
37. Mustard J.F., Rowsell H.C., Murphy E.A. Platelet economy (platelet survival and turnover). Br J Haematol 1966, 12:1-24.
38. Leytin V., Mykhaylov S., Starkey A.F., et al. Intravenous immunoglobulin inhibits anti-glycoprotein iib-induced platelet apoptosis in a murine model of immune thrombocytopenia. Br J Haematol 2006, 133:78-82.
39. Piguet P.F., Vesin C. Modulation of platelet caspases and life-span by anti-platelet antibodies in mice. Eur J Haematol 2002, 68:253-261.
40. Vainchenker W., Deschamps J.F., Bastin J.M., et al. Two monoclonal antiplatelet antibodies as markers of human megakaryocyte maturation: immunofluorescent staining and platelet peroxidase detection in megakaryocyte colonies and in in vivo cells from normal and leukemic patients. Blood 1982, 59:514-521.
41. Mcmillan R., Luiken G.A., Levy R., Yelenosky R., Longmire R.L. Antibody against megakaryocytes in idiopathic thrombocytopenic purpura. JAMA 1978, 239:2460-2462.
42. Mazur E.M., Hoffman R., Chasis J., Marchesi S., Bruno E. Immunofluorescent identification of human megakaryocyte colonies using an antiplatelet glycoprotein antiserum. Blood 1981, 57:277-286.
43. Thiagarajan P., Perussia B., De Marco L., Wells K., Trinchieri G. Membrane proteins on human megakaryocytes and platelets identified by monoclonal antibodies. Am J Hematol 1983, 14:255-269.
44. Chang M., Nakagawa P.A., Williams S.A., et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003, 102:887-895.
45. Mcmillan R., Wang L., Tomer A., Nichol J., Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004, 103:1364-1369.
46. Yang L., Wang L., Zhao C-h, et al. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood 2010, 116:4307-4316.
47. Yoshimura C., Nomura S., Nagahama M., Ozaki Y., Kagawa H., Fukuhara S. Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura. Eur J Haematol 2000, 64:219-224.
48. Imbach P., d'Apuzzo V., Hirt A., et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981, 317:1228-1231.
49. Neunert C., Lim W., Crowther M., Cohen A., Solberg L., Crowther M.A. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011, 117:4190-4207.
50. Provan D., Stasi R., Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115:168-186.
51. Lazarus A.H., Crow A.R. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci 2003, 28:249-255.
52. Imbach P., Lazarus A.H., Kühne T. Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sanguinis 2010, 98:385-394.
53. Von Gunten S., Simon H.U. Cell death modulation by intravenous immunoglobulin. J Clin Immunol 2010, 30(Suppl 1):S24-S30.
54. Von Gunten S., Simon H.U. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (ivig). Autoimmun Rev 2008, 7:453-456.
55. Altznauer F., von Gunten S., Späth P., Simon H.U. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol 2003, 112:1185-1190.
56. Prasad N.K., Papoff G., Zeuner A., et al. Therapeutic preparations of normal polyspecific igg (ivig) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of ivig involving the Fas apoptotic pathway. J Immunol 1998, 161:3781-3790.
57. Sooryanarayana N., Bonnin E., et al. Phosphorylation of Bcl-2 and mitochondrial changes are associated with apoptosis of lymphoblastoid cells induced by normal immunoglobulin G. Biochem Biophys Res Commun 1999, 264:896-901.
58. Von Gunten S., Vogel M., Schaub A., et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol 2007, 119:1005-1011.
59. Von Gunten S., Schaub A., Vogel M., Stadler B.M., Miescher S., Simon H.U. Immunological and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin (ivig) preparations. Blood 2006, 108:4255-4259.
60. Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998, 282:490-493.
61. Schaub A., von Gunten S., Vogel M., et al. Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes. Allergy 2011, 66:1030-1037.
62. Cines D.B., Bussel J.B., Liebman H.A., Luning Prak E.T. The ITP syndrome: pathogenic and clinical diversity. Blood 2009, 113:6511-6521.
63. Kuter D.J., Gernsheimer T.B. Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin North Am 2009, 23:1193-1211.
64. Semple J.W., Provan D., Garvey M.B. Freedman. Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol 2010, 17:590-595.
65. Gernsheimer T. Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis. Oncologist 2009, 14:12-21.